Skip to content

Peripheral blood

PROCEDURE12 trials

Sponsors

Washington University School of Medicine, Mitchell Grayson, National Taiwan University Hospital, Memorial Sloan Kettering Cancer Center, Leids Universitair Medisch Centrum

Conditions

CancerCancer of Head and NeckCarcinoma, Squamous Cell of Head and NeckCovid-19Epithelial Ovarian CancerFallopian Tube CancerHead and Neck CancerHead and Neck Squamous Cell Carcinoma

Phase 1

BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
CompletedNCT03496662
Washington University School of MedicinePancreatic Ductal Adenocarcinoma
Start: 2018-08-31End: 2024-07-25Updated: 2025-07-29
Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
CompletedNCT03532217
Washington University School of MedicineMetastatic Hormone-Sensitive Prostate Cancer
Start: 2018-09-14End: 2022-07-25Updated: 2022-08-05
Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy
WithdrawnNCT03607955
Washington University School of MedicineEpithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Start: 2021-06-30End: 2029-08-31Updated: 2021-09-29
Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Active, not recruitingNCT03650764
Washington University School of MedicineHead and Neck Squamous Cell Carcinoma
Start: 2019-05-29End: 2026-06-30Updated: 2025-12-30
Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy
TerminatedNCT03655444
Washington University School of MedicineHead and Neck Squamous Cell Carcinoma
Start: 2019-05-29End: 2020-08-24Updated: 2020-12-03

Phase 2

Unknown Phase

Related Papers

5 more papers not shown